PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model

Li, Pan, Asokanathanb, Catpagavalli, Liu, Fang, Khaing, Kyi Kyi, Kmiec, Dorota, Wei, Xiaoqing, Song, Bin, Xing, Dorothy and Kong, Deling (2016) PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model. International Journal of Pharmaceutics, 513 (1-2). pp. 183-190. ISSN 0378-5173

Copy

Poly(lactic-co-glycolic acid) (PLGA) based nano/micro particles were investigated as a potential vaccine platform for pertussis antigen. Presentation of pertussis toxoid as nano/micro particles (NP/MP) gave similar antigen-specific IgG responses in mice compared to soluble antigen. Notably, in cell line based assays, it was found that PLGA based nano/micro particles enhanced the phagocytosis of fluorescent antigen-nano/micro particles by J774.2 murine monocyte/macrophage cells compared to soluble antigen. More importantly, when mice were immunised with the antigen-nano/micro particles they significantly increased antigen-specific Th1 cytokines INF-γ and IL-17 secretion in splenocytes after in vitro re-stimulation with heat killed Bordetalla pertussis, indicating the induction of a Th1/Th17 response. Also, presentation of pertussis antigen in a NP/MP formulation is able to provide protection against respiratory infection in a murine model. Thus, the NP/MP formulation may provide an alternative to conventional acellular vaccines to achieve a more balanced Th1/Th2 immune response.

Item Type	Article
Additional information	This document is the Accepted Manuscript version of the following article: Pan Li, Catpagavalli Asokanathan, Fang Liu, Kyi Kyi Khaing, Dorota Kmiec, Xiaoqing Wei, Sing Song, Dorothy Xing, and Deling Kong, ‘PLGA nano/micro particles encapsulated with pertussis toxoid (PTd) enhances Th1/Th17 immune response in a murine model’, International Journal of Pharmaceutics, Vol. 513 (1-2): 183-190, November 2016, available online at: https://doi.org/10.1016/j.ijpharm.2016.08.059. This manuscript version is made available under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives LicenseCC BY NC-ND 4.0 ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Date Deposited	15 May 2025 13:22
Last Modified	01 Jun 2025 00:32